FDA gives Priority Review to Celgene's ABRAXANE sNDA for advanced pancreatic cancer

[News]

Celgene International SÃ*rl, a subsidiary of Celgene Corporation today announced that the U.S. Food and Drug Administration has assigned a Priority Review designation to the supplemental New Drug Application for the use of ABRAXANE (paclitaxel protein-bound particles for injectable suspension) (albumin-bound) in combination with gemcitabine for the first-line treatment of patients with advanced pancreatic cancer.

More... (http://www.news-medical.net/news/20130523/FDA-gives-Priority-Review-to-Celgenes-ABRAXANE-sNDA-for-advanced-pancreatic-cancer.aspx)